Ye Guo

4.3k total citations
217 papers, 2.3k citations indexed

About

Ye Guo is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Ye Guo has authored 217 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Oncology, 52 papers in Hematology and 46 papers in Molecular Biology. Recurrent topics in Ye Guo's work include Acute Lymphoblastic Leukemia research (37 papers), Lymphoma Diagnosis and Treatment (35 papers) and Acute Myeloid Leukemia Research (30 papers). Ye Guo is often cited by papers focused on Acute Lymphoblastic Leukemia research (37 papers), Lymphoma Diagnosis and Treatment (35 papers) and Acute Myeloid Leukemia Research (30 papers). Ye Guo collaborates with scholars based in China, United States and Singapore. Ye Guo's co-authors include Wei Cui, Donghong Zhang, Xiaonan Hong, Xuejun Ma, Biyun Wang, Xiaofan Zhu, Chaosu Hu, Lin Kong, Jiade J. Lu and Danfei Xu and has published in prestigious journals such as The Lancet, Nucleic Acids Research and Nature Communications.

In The Last Decade

Ye Guo

184 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ye Guo China	28	1.0k	684	412	393	336	217	2.3k
Mustafa Beneklı Türkiye	24	1.2k 1.2×	623 0.9×	470 1.1×	601 1.5×	279 0.8×	182	2.6k
Dusan Kotasek Australia	28	1.2k 1.1×	448 0.7×	371 0.9×	542 1.4×	282 0.8×	104	2.3k
Robert S. Lavey United States	25	724 0.7×	520 0.8×	143 0.3×	498 1.3×	367 1.1×	52	2.5k
Jung Yong Hong South Korea	25	1.2k 1.2×	509 0.7×	607 1.5×	605 1.5×	353 1.1×	194	2.3k
Feng‐Hua Wang China	31	1.5k 1.5×	872 1.3×	331 0.8×	861 2.2×	822 2.4×	126	2.9k
Felix Chu United States	12	632 0.6×	588 0.9×	251 0.6×	539 1.4×	238 0.7×	19	1.7k
S.C. Henzen‐Logmans Netherlands	29	1.2k 1.1×	862 1.3×	326 0.8×	366 0.9×	811 2.4×	60	2.7k
Thorsten Fuereder Austria	21	804 0.8×	448 0.7×	166 0.4×	387 1.0×	180 0.5×	92	1.5k
Simon Thézenas France	29	1.7k 1.7×	830 1.2×	345 0.8×	786 2.0×	723 2.2×	117	3.0k
Yan Qin China	22	781 0.8×	641 0.9×	479 1.2×	405 1.0×	386 1.1×	131	1.8k

Countries citing papers authored by Ye Guo

Since Specialization

Citations

This map shows the geographic impact of Ye Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ye Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ye Guo more than expected).

Fields of papers citing papers by Ye Guo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ye Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ye Guo. The network helps show where Ye Guo may publish in the future.

Co-authorship network of co-authors of Ye Guo

This figure shows the co-authorship network connecting the top 25 collaborators of Ye Guo. A scholar is included among the top collaborators of Ye Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ye Guo. Ye Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tang, Lin‐Quan, Sai-Lan Liu, Muh‐Hwa Yang, et al.. (2025). GFH018 and Toripalimab Combination Therapy for Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: Results from a Phase Ib/II Study. Clinical Cancer Research. 31(16). 3424–3432.

Luo, Zhibing, Yue Zheng, Ye Guo, et al.. (2025). A pilot study of endobronchial repairment for bronchopleural fistulas. Respiratory Research. 26(1). 55–55.

Zhang, Yiming, Dandan Ma, Ye Guo, et al.. (2025). Ultra Electron-Donating Segment-Dependence of NIR-II Absorbing Aza-boron-dipyrromethenes for Photothermal-Photodynamic Phototherapy of Breast Cancer. ACS Materials Letters. 7(12). 3844–3852.

Lü, Shun, Ying Cheng, Dingzhi Huang, et al.. (2025). Selpercatinib in Chinese patients with RET -fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the LIBRETTO-321 phase II trial. Therapeutic Advances in Medical Oncology. 17. 12751935–12751935.

Sangro, Bruno, Mingliang Zhang, Hui Zhang, et al.. (2025). 1494P Pooled efficacy and safety outcomes with tremelimumab plus durvalumab in participants (pts) with unresectable hepatocellular carcinoma (uHCC) from the combined China extension and global cohorts in the phase III HIMALAYA study. Annals of Oncology. 36. S832–S833.

Ren, Yuanyuan, Fang Liu, Xia Chen, et al.. (2024). Decitabine-containing conditioning improved outcomes for children with higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation. Annals of Hematology. 103(4). 1345–1351. 1 indexed citations

Li, Jun, Yangyang Gao, Yang Wan, et al.. (2024). Minimal residual disease monitoring in childhood Philadelphia-positive acute lymphoblastic leukemia: prognostic significance and correlation between multiparameter flow cytometry and real-time quantitative polymerase chain reaction. Haematologica. 109(12). 4089–4094. 1 indexed citations

Xue, Junli, Yan Zhang, Xudong Hu, et al.. (2024). Phase I/II safety and preliminary efficacy of PM1022, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). e14694–e14694. 2 indexed citations

Guo, Ye, Lihua Wu, Yong Li, et al.. (2024). First-in-human phase I/II safety and preliminary efficacy of PM1032, a bispecific antibody targeting CLDN18.2 and 4-1BB, in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2662–2662. 3 indexed citations

10.

Tian, Yan, et al.. (2024). GLP-1/GIP dual agonist tirzepatide normalizes diabetic nephropathy via PI3K/AKT mediated suppression of oxidative stress. International Immunopharmacology. 146. 113877–113877. 5 indexed citations

11.

Xue, Liqiong, Wenbo Tang, Junli Xue, et al.. (2023). Next-generation sequencing identifies CDKN2A alterations as prognostic biomarkers in recurrent or metastatic head and neck squamous cell carcinoma predominantly receiving immune checkpoint inhibitors. Frontiers in Oncology. 13. 1276009–1276009. 6 indexed citations

12.

Ma, Yuxiang, Yuanyuan Zhao, Yang Zhang, et al.. (2023). Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 11(6). e006654–e006654. 34 indexed citations

13.

Cheng, Ying, Dingzhi Huang, Jianying Zhou, et al.. (2023). Intracranial Activity of Selpercatinib in Chinese Patients With AdvancedRETFusion–Positive Non–Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial. JCO Precision Oncology. 7(7). e2200708–e2200708. 3 indexed citations

14.

Ying, Zhitao, Haiyan Yang, Ye Guo, et al.. (2023). Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study. Cytotherapy. 25(5). 521–529. 13 indexed citations

15.

Song, Yuqin, Zhitao Ying, Haiyan Yang, et al.. (2021). Relmacabtagene Autoleucel CD19 CART Therapy for Adults with Heavily-Pretreated Relapsed/Refractory Large B-Cell Lymphoma in China. Blood. 138(Supplement 1). 3557–3557. 2 indexed citations

16.

Guo, Ye, et al.. (2020). [Efficacy and prognostic factors of the chemotherapy regimen of CCLG-ALL-2008 on pediatric acute lymphoblastic leukemia with ETV6-RUNX1 rearrangement].. PubMed. 41(11). 896–902. 1 indexed citations

17.

Yang, Wenyu, Ye Guo, Xiaojuan Chen, et al.. (2017). The Correlation Studies between Central Nervous System Involvement By Flow Cytometry and the Prognosis of Children Acute Lymphoblastic Leukemia: A Single Chinese Center's Experience By Cclg- ALL 2008. Blood. 130. 1293–1293. 1 indexed citations

18.

Zhang, Jiayuan, Li Zhang, Lixian Chang, et al.. (2015). [Genotype analysis and telomere length measure in patients with dyskeratosis congenita].. PubMed. 23(1). 212–6. 2 indexed citations

19.

Kong, Lin, et al.. (2012). Neoadjuvant Chemotherapy With TPF Regimen Followed by Concurrent Chemoradiation for Locoregionally Advanced Stage Nasopharyngeal Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 84(3). S487–S487. 1 indexed citations

20.

Yang, Zhuo, et al.. (2011). Detection and clinical significance of EGFR and KRAS mutation in peripheral blood from tumor patients by REDE-DHPLC. Zhonghua jianyan yixue zazhi. 34(4). 327–332. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact